Definium Therapeutics' LSD-Based Psych Drug Scores Again

· investors.com

Definium Therapeutics unveiled the second of two positive Phase 3 studies for its LSD-based drug. The biotech stock surged on the results.

Definium Therapeutics (DFTX) unveiled the second of two positive Phase 3 studies for its LSD-based drug. The biotech stock surged on the results. Patients with ...


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI